Artificial pancreas may turn out as a promising investment for diabetes patients

The World Health Organisation estimates that about 9% of people worldwide have diabetes. The majority (>90%) of these people have type 2 diabetes, which is quickly rising due to rising obesity rates and an ageing population. Less people (>10%) have type 1 diabetes, which typically first manifests in childhood. In terms of technical and regulatory difficulties, the patient population and added complexity of glucagon addition to a pump account for why many manufacturers concentrate only on insulin pumps and why those with type 1 diabetes are unsatisfied with the currently marketed artificial pancreas systems.

Managing diabetes can be challenging, with patients having to constantly monitor their blood sugar levels, adjust insulin dosages, and make lifestyle changes to manage their condition. However, with recent advancements in medical technology, there is hope for diabetes patients in the form of the artificial pancreas.

An artificial pancreas is a device that closely mimics the function of a healthy pancreas by continuously monitoring blood sugar levels and delivering insulin as needed. The device consists of three components: a continuous glucose monitor, an insulin pump, and a control algorithm that regulates insulin delivery based on the patient's glucose levels.

Researchers have found that an artificial pancreas developed by the UVA Center for Diabetes Technology can help improve blood sugar control in people with Type 1 diabetes. The system, known as the Control-IQ system, consists of an insulin pump that automatically monitors and regulates blood glucose levels based on the patient's glucose-monitoring information. The analysis of three clinical trials involving nearly 370 patients found that those using the artificial pancreas system saw improvements in their average blood sugar levels, with an A1c decrease of 0.5 percent compared to a decrease of just 0.1 percent for patients in the control groups. The findings have been published in the journal Diabetes Technology and Therapeutics.

Investing in the development and commercialization of artificial pancreas technology has the potential to bring significant benefits to diabetes patients. Here are some of the key advantages:

The artificial pancreas can provide more precise and consistent insulin dosages than traditional insulin therapy, leading to better glucose control and reducing the risk of hypoglycemia and hyperglycemia.
Diabetes patients no longer have to manually monitor their blood sugar levels and inject insulin, which can be time-consuming and cumbersome. With the artificial pancreas, insulin delivery is automated and requires minimal user input, making diabetes management easier and more convenient.
Diabetes can have a significant impact on a patient's quality of life, with the constant need for monitoring and insulin administration affecting daily activities and emotional well-being. The artificial pancreas can alleviate some of these burdens, allowing patients to live more normal lives.

Investing in the development and commercialization of artificial pancreas technology is also a smart business move. According to BioIntel360 market report, the global diabetes market is expected to reach $146.89 billion by 2025, with a growing demand for innovative therapies to manage the condition. Companies that are at the forefront of artificial pancreas technology stand to benefit from this trend, both in terms of revenue and reputation.

For people with Type 1 diabetes of all ages, Tandem Diabetes Care has already demonstrated that its closed-loop system for automated insulin delivery can increase the amount of time spent in range. However, a new study credits the system's automatic correction bolusing capabilities with some of the strongest improvements in those results.
In a recent study supported by the NIH and directed by Dr. Marc Breton from the University of Virginia, an artificial pancreas was evaluated in children with Type 1 diabetes between the ages of 2 and 5. The study suggested that artificial pancreas systems could potentially improve blood glucose control throughout the day, including at night. This can help alleviate concerns that families have about low blood glucose levels and the long-term effects of Type 1 diabetes on their children's health.

However, there are still challenges to be overcome in the adoption of artificial pancreas technology. Cost is a significant factor, with the devices currently being expensive and not covered by all insurance plans. There are also concerns around the safety and reliability of the technology, with some patients experiencing technical issues and malfunctions.

Despite these challenges, the benefits of artificial pancreas technology cannot be ignored. As technology improves and costs come down, the adoption of artificial pancreas devices is likely to increase. Investing in this promising technology has the potential to bring significant benefits to diabetes patients, while also being a sound business decision for companies looking to capitalize on the growing diabetes market.